

**RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT
MULTICENTER PROSPECTIVE PHASE II STUDY OF DA**

Hematological Oncology

35, 133-134

DOI: [10.1002/hon.2437_122](https://doi.org/10.1002/hon.2437_122)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective. Blood, 2018, 132, 369-375. | 0.6 | 32 |
| 2 | Optimizing treatment of HIV-associated lymphoma. Blood, 2019, 134, 1385-1394. | 0.6 | 63 |
| 3 | Recent Advances in Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2019, 14, 106-118. | 1.2 | 21 |
| 4 | Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood, 2019, 133, 1313-1324. | 0.6 | 172 |
| 5 | Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. Cancer Medicine, 2020, 9, 77-83. | 1.3 | 15 |
| 6 | Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. European Journal of Cancer, 2020, 138, 189-192. | 1.3 | 5 |
| 7 | HIV Lymphoma and Burkitts Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 260-268. | 1.0 | 13 |
| 8 | Dose-adjusted EPOCH: a feasible alternative for Burkitt lymphoma in resource-constrained settings. British Journal of Haematology, 2020, 190, e362-e363. | 1.2 | 2 |
| 9 | Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma. Current Treatment Options in Oncology, 2021, 22, 60. | 1.3 | 6 |
| 10 | Burkitt Lymphoma. Technik Im Fokus, 2019, , 167-175. | 0.2 | 0 |